Who are Tivicay's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Hydroxychloroquin, Tivicay, AZAPERONE, Hepsera, ABACAVIR SULFATE, Epivir.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dolutegravir.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Tivicay — Competitive Intelligence Brief

Tivicay (DOLUTEGRAVIR) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]. Area: Immunology.

marketed Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] Transmembrane protein 97 Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Tivicay (DOLUTEGRAVIR) — GSK. Tivicay blocks the integrase enzyme, preventing HIV from integrating its genetic material into the host cell's DNA.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tivicay TARGET	DOLUTEGRAVIR	GSK	marketed	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]	Transmembrane protein 97	2013-01-01
Hydroxychloroquin	Hydroxychloroquin	Children's Hospital of Fudan University	marketed		Transmembrane protein 97, Alpha-1D adrenergic receptor, Alpha-2A adrenergic receptor
Tivicay	Tivicay	St Stephens Aids Trust	marketed		Transmembrane protein 97, Integrase, Integrase
AZAPERONE	AZAPERONE		marketed		D(4) dopamine receptor, Transmembrane protein 97, 5-hydroxytryptamine receptor 1A
Hepsera	ADEFOVIR DIPIVOXIL	Gilead Sciences	marketed	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor	DNA polymerase subunit gamma-1	2002-01-01
ABACAVIR SULFATE	ABACAVIR SULFATE		marketed	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]		1998-01-01
Epivir	LAMIVUDINE	GSK	marketed	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]	Deoxycytidine kinase	1995-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class)

GSK · 3 drugs in this class
· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tivicay — Competitive Intelligence Brief. https://druglandscape.com/ci/dolutegravir. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab